Budget impact of Claseprubart
1 evidence topic · 4 sources
Summary
No price for claseprubart has been announced and no budget impact model of claseprubart has been published. A company investor presentation states an assumed average biologic net price per patient of approximately $400,000 per year for the generalized myasthenia gravis market.
Published cost-effectiveness analyses include evaluations of eculizumab and efgartigimod. In the 2021 ICER evaluation over a 2-year horizon, eculizumab at an estimated annual cost of $653,100 had an incremental cost-effectiveness ratio of $5,210,000 per QALY/evLYG, and efgartigimod at a placeholder price of $418,400 had $2,076,000 per QALY/evLYG; the health benefit price benchmark was $13,200 to $19,400 for eculizumab and $18,300 to $28,400 for efgartigimod, and 8.8% of the eligible population could be treated with efgartigimod at the placeholder price without passing ICER's budget impact threshold. A Markov model with a lifetime horizon estimated $3,338,000 per QALY gained for eculizumab and found that eculizumab and efgartigimod would need discounts of 93.01% and 88.34% of the base-case price to be cost-effective.